Grupo para la caracterización molecular de las neoplasias hematológicas
Erasmus University Medical Center
Róterdam, HolandaPublicaciones en colaboración con investigadores/as de Erasmus University Medical Center (32)
2021
-
Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group
Leukemia, Vol. 35, Núm. 12, pp. 3585-3588
-
Trends in allogeneic haematopoietic cell transplantation for myelofibrosis in Europe between 1995 and 2018: a CMWP of EBMT retrospective analysis
Bone Marrow Transplantation, Vol. 56, Núm. 9, pp. 2160-2172
2020
-
Characteristics and outcome of adult patients with acute promyelocytic leukemia and increased body mass index treated with the PETHEMA Protocols
European Journal of Haematology, Vol. 104, Núm. 3, pp. 162-169
2019
-
An analysis of the impact of CD56 expression in de novo acute promyelocytic leukemia patients treated with upfront all-trans retinoic acid and anthracycline-based regimens
Leukemia and Lymphoma, Vol. 60, Núm. 4, pp. 1030-1035
2018
-
Maintenance Treatment and Survival in Patients with Myeloma: A Systematic Review and Network Meta-analysis
JAMA Oncology, Vol. 4, Núm. 10, pp. 1389-1397
2017
-
Differentiation stage of myeloma plasma cells: Biological and clinical significance
Leukemia, Vol. 31, Núm. 2, pp. 382-392
-
Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma
Leukemia, Vol. 31, Núm. 10, pp. 2094-2103
2016
-
International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment
Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557
-
Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients
Blood, Vol. 127, Núm. 25, pp. 3165-3174
2015
-
All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: A matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies
Annals of Hematology, Vol. 94, Núm. 8, pp. 1347-1356
-
Revised international staging system for multiple myeloma: A report from international myeloma working group
Journal of Clinical Oncology, Vol. 33, Núm. 26, pp. 2863-2869
-
Role of magnetic resonance imaging in the management of patients with multiple myeloma: A consensus statement
Journal of Clinical Oncology, Vol. 33, Núm. 6, pp. 657-664
2014
-
Application of a 5-tiered scheme for standardized classification of 2,360 unique mismatch repair gene variants in the InSiGHT locus-specific database
Nature Genetics, Vol. 46, Núm. 2, pp. 107-115
-
Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study
American Journal of Hematology, Vol. 89, Núm. 4, pp. 355-362
-
Combination of International Scoring System 3, highlactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related death
Journal of Clinical Oncology, Vol. 32, Núm. 20, pp. 2173-2180
-
New drugs and novel mechanisms of action in multiple myeloma in 2013: A report from the International Myeloma Working Group (IMWG)
Leukemia, Vol. 28, Núm. 3, pp. 525-542
-
Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions
New England Journal of Medicine, Vol. 370, Núm. 12, pp. 1101-1110
2013
-
Age and organ damage correlate with poor survival in myeloma patients: Meta-analysis of 1435 individual patient data from 4 randomized trials
Haematologica, Vol. 98, Núm. 6, pp. 980-987
-
Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: A meta-analysis of phase III randomized, controlled trials
Journal of Clinical Oncology, Vol. 31, Núm. 26, pp. 3279-3287
-
Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: An International Myeloma Working Group collaborative project
Leukemia, Vol. 27, Núm. 3, pp. 711-717